# US 8,569,261 B2 · Vascular protecting agent having salt-absorption inhibitory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,261 B2
- Document ID: US8569261B2
- Status: Granted
- Kind: B2
- Application number: 13/219,969
- Filed: 2011-08-29
- Published: 2012-03-08
- Granted: 2013-10-29
- Earliest claimed: 2010-08-31
- Assignees: Maruha Nichiro Foods, Inc.
- Applicants: Itsuki Murota; Yoshio Uehara
- Inventors: Itsuki Murota; Yoshio Uehara
- Web page: https://patentgrep.com/patent/US8569261B2

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61P 3/12: for electrolyte homeostasis
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- C12N 1/205: Bacterial isolates
- C12P 19/00: Preparation of compounds containing saccharide radicals (ketoaldonic acids C12P7/58)
- C12R 2001/38: Pseudomonas
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

This invention provides a vascular protecting agent having salt-absorption inhibitory activity with the use of alginate oligosaccharide salt absorbed by the body via degradation to an oligosaccharide, so that a patient can easily and safely ingest such agent on a routine basis. A vascular protecting agent having salt-absorption inhibitory activity comprises, as an active ingredient, alginate oligosaccharide obtained by treating sodium alginate with a Pseudoalteromonas microorganism or a processed product thereof and/or a salt thereof.

## Claims

### Claim 1

A method for suppressing thickening of the blood vessel by inhibiting salt-absorption, which comprises administering an alginate oligosaccharide and/or salt thereof to a patient in need thereof, wherein the alginate oligosaccharide and/or salt thereof of formula 1:
wherein in formula 1,
R is a hydrogen atom or a metal ion;
R′ is a structure selected from the group consisting of G; G-G; M-G; G-G-G; G-G-M; G-M-G; G-M-M; M-G-G; M-M-G; and M-M-M, wherein the linkage among D-mannuronic acid (M) and L-guluronic acid (G) is α- or β-1,4-bound.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the alginate oligosaccharide and/or salt thereof is obtained by treating sodium alginate with a Pseudoalteromonas microorganism.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the Pseudoalteromonas microorganism is the Pseudoalteromonas sp. strain No. 1786.

### Claim 4

A method for suppressing cardiac hypertrophy by protecting a vascular, which comprises administering an alginate oligosaccharide and/or salt thereof to a patient in need thereof, wherein the alginate oligosaccharide and/or salt thereof of formula 1:
wherein in formula 1,
R is a hydrogen atom or a metal ion;
R′ is a structure selected from the group consisting of G; G-G; M-G; G-G-G; G-G-M; G-M-G; G-M-M; M-G-G; M-M-G; and M-M-M, wherein the linkage among D-mannuronic acid (M) and L-guluronic acid (G) is α- or β-1,4-bound.

### Claim 5

A method for suppressing renal hypertrophy and/or glomerular hardening by protecting a vascular, which comprises administering an alginate oligosaccharide and/or salt thereof to a patient in need thereof, wherein the alginate oligosaccharide and/or salt thereof of formula 1:
wherein in formula 1,
R is a hydrogen atom or a metal ion;
R′ is a structure selected from the group consisting of G; G-G; M-G; G-G-G; G-G-M; G-M-G; G-M-M; M-G-G; M-M-G; and M-M-M, wherein the linkage among D-mannuronic acid (M) and L-guluronic acid (G) is α- or β-1,4-bound.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the alginate oligosaccharide and/or salt thereof is subcutaneously administered.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the alginate oligosaccharide and/or salt thereof is subcutaneously administered.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the alginate oligosaccharide and/or salt thereof is subcutaneously administered.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the alginate oligosaccharide and/or salt thereof is obtained by treating sodium alginate with a Pseudoalteromonas microorganism.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the Pseudoalteromonas microorganism is the Pseudoalteromonas sp. strain No. 1786.

### Claim 11 (depends on 5)

The method according to claim 5, wherein the alginate oligosaccharide and/or salt thereof is obtained by treating sodium alginate with a Pseudoalteromonas microorganism.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the Pseudoalteromonas microorganism is the Pseudoalteromonas sp. strain No. 1786.